Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1186/s13058-017-0884-8.

Title:
Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance | Breast Cancer Research
Description:
Background The effects of neoadjuvant chemotherapy on immune markers remain largely unknown. The specific aim of this study was to assess stromal tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) protein expression in a cohort of breast cancer patients treated with neoadjuvant chemotherapy. Methods Using quantitative immunofluorescence, we investigated stromal TILs and PD-L1 protein expression in pre-treatment and residual breast cancer tissue from a Yale Cancer Center patient cohort of 58 patients diagnosed with breast cancer from 2003 to 2009 and treated with neoadjuvant chemotherapy. We compared the TIL count and PD-L1 status in paired pre-treatment and residual cancer tissues and correlated changes and baseline levels with survival. Results Of the 58 patients, 46 (79.3%) had hormone-positive and 34 (58.6%) had node-positive breast cancer. Eighty-six percent of residual cancer tissues had TIL infiltration and 17% had PD-L1 expression. There was a trend for higher TIL counts in postchemotherapy compared to prechemotherapy samples (p = 0.09). Increase in TIL count was associated with longer 5-year recurrence-free survival (p = 0.02, HR = 3.9, 95% CI = 1.179–15.39). PD-L1 expression (both stromal and tumor cells) was significantly lower in post-treatment samples (p = 0.001). Change in PD-L1 expression after therapy or TILs and PD-L1 expression in the posttreatment samples did not correlate with survival. Conclusions Increase in stromal TILs in residual cancer compared to pretreatment tissue is associated with improved recurrence-free survival. Despite a trend for increasing TIL counts, PD-L1 expression decreased in residual disease compared to pretreatment samples.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Education
  • Health & Fitness
  • Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

cancer, pdl, breast, expression, til, article, neoadjuvant, tumor, chemotherapy, residual, pubmed, tils, google, scholar, cases, cas, lymphocytes, stromal, treatment, data, baseline, survival, immune, study, patients, response, clin, analysis, tumorinfiltrating, pretreatment, disease, count, specimens, change, rimm, postneoadjuvant, qif, tissue, counts, oncol, cell, additional, res, compared, status, studies, scores, research, tissues, cells,

Topics {✒️}

jason brown & david pd-1/pd-l1-based treatments programmed death ligand-1 programmed death-ligand 1 subtype-specific metagene-based prediction bristol-myers squibb activate anti-tumor immunity pre-treatment pd-l1 assessment triple-negative breast cancer node-positive breast cancer full size image tumor-infiltrating foxp3+ regulatory neoadjuvant her2-directed therapies promote pd-l1-mediated reduced tumor-infiltrating lymphocytes early-stage breast cancer incorporating multi-institution cohorts article download pdf high-risk breast cancer pd-l1 expression decreased quantify pd-l1 expression pd-l1 expression correlates jason brown immune cell pd-l1 displays low pd-l1 adaptive resistance mechanism combined pd-axis blockade pd-l1-expressing cells post-neoadjuvant resection specimens showing pd-l1 expression small-cell lung cancer pd-l1 protein expression high pd-l1 expression pd-l1 multiplexed assay multiple immune-parameter modulation improved recurrence-free survival year recurrence-free survival low pd-l1 expression pd-l1 sp142 antibody dab-based chromogen visualization iii breast cancer pd-l1 expression prior pd-l1 protein levels stromal/immune cell scoring tumor-infiltrating lymphocytes analysis tumor pd-l1 levels ligand pd-l1 immune-related effect national cancer database post-neoadjuvant treatment based

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
         description:The effects of neoadjuvant chemotherapy on immune markers remain largely unknown. The specific aim of this study was to assess stromal tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) protein expression in a cohort of breast cancer patients treated with neoadjuvant chemotherapy. Using quantitative immunofluorescence, we investigated stromal TILs and PD-L1 protein expression in pre-treatment and residual breast cancer tissue from a Yale Cancer Center patient cohort of 58 patients diagnosed with breast cancer from 2003 to 2009 and treated with neoadjuvant chemotherapy. We compared the TIL count and PD-L1 status in paired pre-treatment and residual cancer tissues and correlated changes and baseline levels with survival. Of the 58 patients, 46 (79.3%) had hormone-positive and 34 (58.6%) had node-positive breast cancer. Eighty-six percent of residual cancer tissues had TIL infiltration and 17% had PD-L1 expression. There was a trend for higher TIL counts in postchemotherapy compared to prechemotherapy samples (p = 0.09). Increase in TIL count was associated with longer 5-year recurrence-free survival (p = 0.02, HR = 3.9, 95% CI = 1.179–15.39). PD-L1 expression (both stromal and tumor cells) was significantly lower in post-treatment samples (p = 0.001). Change in PD-L1 expression after therapy or TILs and PD-L1 expression in the posttreatment samples did not correlate with survival. Increase in stromal TILs in residual cancer compared to pretreatment tissue is associated with improved recurrence-free survival. Despite a trend for increasing TIL counts, PD-L1 expression decreased in residual disease compared to pretreatment samples.
         datePublished:2017-08-07T00:00:00Z
         dateModified:2017-09-25T00:00:00Z
         pageStart:1
         pageEnd:11
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s13058-017-0884-8
         keywords:
            Tumor infiltrating lymphocytes
            Programmed death ligand 1
            Neoadjuvant treatment
            Breast cancer
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13058-017-0884-8/MediaObjects/13058_2017_884_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13058-017-0884-8/MediaObjects/13058_2017_884_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13058-017-0884-8/MediaObjects/13058_2017_884_Fig3_HTML.gif
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:19
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Vasiliki Pelekanou
               url:http://orcid.org/0000-0002-8431-1927
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Pathology, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Daniel E. Carvajal-Hausdorf
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Pathology, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mehmet Altan
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Brad Wasserman
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Pathology, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Cristobal Carvajal-Hausdorf
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hallie Wimberly
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Pathology, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jason Brown
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Pathology, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Donald Lannin
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Surgery, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lajos Pusztai
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:David L. Rimm
               affiliation:
                     name:Yale University School of Medicine
                     address:
                        name:Department of Pathology, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
                     name:Yale University School of Medicine
                     address:
                        name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
      description:The effects of neoadjuvant chemotherapy on immune markers remain largely unknown. The specific aim of this study was to assess stromal tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) protein expression in a cohort of breast cancer patients treated with neoadjuvant chemotherapy. Using quantitative immunofluorescence, we investigated stromal TILs and PD-L1 protein expression in pre-treatment and residual breast cancer tissue from a Yale Cancer Center patient cohort of 58 patients diagnosed with breast cancer from 2003 to 2009 and treated with neoadjuvant chemotherapy. We compared the TIL count and PD-L1 status in paired pre-treatment and residual cancer tissues and correlated changes and baseline levels with survival. Of the 58 patients, 46 (79.3%) had hormone-positive and 34 (58.6%) had node-positive breast cancer. Eighty-six percent of residual cancer tissues had TIL infiltration and 17% had PD-L1 expression. There was a trend for higher TIL counts in postchemotherapy compared to prechemotherapy samples (p = 0.09). Increase in TIL count was associated with longer 5-year recurrence-free survival (p = 0.02, HR = 3.9, 95% CI = 1.179–15.39). PD-L1 expression (both stromal and tumor cells) was significantly lower in post-treatment samples (p = 0.001). Change in PD-L1 expression after therapy or TILs and PD-L1 expression in the posttreatment samples did not correlate with survival. Increase in stromal TILs in residual cancer compared to pretreatment tissue is associated with improved recurrence-free survival. Despite a trend for increasing TIL counts, PD-L1 expression decreased in residual disease compared to pretreatment samples.
      datePublished:2017-08-07T00:00:00Z
      dateModified:2017-09-25T00:00:00Z
      pageStart:1
      pageEnd:11
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s13058-017-0884-8
      keywords:
         Tumor infiltrating lymphocytes
         Programmed death ligand 1
         Neoadjuvant treatment
         Breast cancer
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13058-017-0884-8/MediaObjects/13058_2017_884_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13058-017-0884-8/MediaObjects/13058_2017_884_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13058-017-0884-8/MediaObjects/13058_2017_884_Fig3_HTML.gif
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:19
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Vasiliki Pelekanou
            url:http://orcid.org/0000-0002-8431-1927
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Pathology, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Daniel E. Carvajal-Hausdorf
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Pathology, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mehmet Altan
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Brad Wasserman
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Pathology, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Cristobal Carvajal-Hausdorf
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hallie Wimberly
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Pathology, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jason Brown
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Pathology, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Donald Lannin
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Surgery, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lajos Pusztai
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David L. Rimm
            affiliation:
                  name:Yale University School of Medicine
                  address:
                     name:Department of Pathology, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
                  name:Yale University School of Medicine
                  address:
                     name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:19
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Yale University School of Medicine
      address:
         name:Department of Pathology, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Pathology, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Pathology, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Pathology, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Pathology, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Surgery, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Pathology, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Vasiliki Pelekanou
      url:http://orcid.org/0000-0002-8431-1927
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Pathology, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Daniel E. Carvajal-Hausdorf
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Pathology, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Mehmet Altan
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Brad Wasserman
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Pathology, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Cristobal Carvajal-Hausdorf
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Hallie Wimberly
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Pathology, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Jason Brown
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Pathology, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Donald Lannin
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Surgery, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:Lajos Pusztai
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      name:David L. Rimm
      affiliation:
            name:Yale University School of Medicine
            address:
               name:Department of Pathology, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
            name:Yale University School of Medicine
            address:
               name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Pathology, Yale University School of Medicine, New Haven, USA
      name:Department of Pathology, Yale University School of Medicine, New Haven, USA
      name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
      name:Department of Pathology, Yale University School of Medicine, New Haven, USA
      name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
      name:Department of Pathology, Yale University School of Medicine, New Haven, USA
      name:Department of Pathology, Yale University School of Medicine, New Haven, USA
      name:Department of Surgery, Yale University School of Medicine, New Haven, USA
      name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA
      name:Department of Pathology, Yale University School of Medicine, New Haven, USA
      name:Department of Medical Oncology, Yale University School of Medicine, New Haven, USA

External Links {🔗}(165)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

4.94s.